The focus on China as a threat misses the larger trend: key biotech processes like antibody discovery have become so standardized and cheap that they are now commodities. If China hadn't filled this role, another country would have.
America's high drug prices, while socially debated, ensure that global biotech innovators, including those in China, prioritize bringing their best drugs to the US market. This guarantees American access to cutting-edge treatments developed anywhere.
The most significant long-term risk to US biotech isn't foreign competition but the degradation of its basic research environment. This system attracts top global talent, and its decline will have ramifications for decades.
While AI for designing novel molecules gets the hype, its practical, near-term impact is in streamlining operational tasks like summarizing medical charts, preparing SEC filings, and analyzing contracts, which are a better fit for current LLM capabilities.
As anyone can easily obtain an antibody for a target, the value of a single patent on a construct decreases. The real premium and competitive advantage will come from late-stage clinical development, clever indication selection, and superior trial execution.
AI startups may solve one piece of the 150-problem drug discovery puzzle exceptionally well. However, they lack the scale to run enough experiments to prove their specific edge provides overall value, making them likely acquisition targets for Big Pharma's toolkits.
China’s efficiency in early-stage clinical trials is not a threat but a global asset. It allows for faster generation of proof-of-concept data, which helps de-risk programs for all companies before they undertake expensive, global trials for FDA approval.